Bjurlin, M. A. et al. Update of the standard operating procedure on the use of multiparametric magnetic resonance imaging for the diagnosis, staging and management of prostate cancer. J. Urol. 203, 706–712 (2020).
Mottet, N. et al. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer — 2020 update. Part 1: screening, diagnosis, and local treatment with curative intent. Eur. Urol. 79, 243–262 (2021).
CAS PubMed Article Google Scholar
Mason, B. R. et al. Current status of MRI and PET in the NCCN guidelines for prostate cancer. J. Natl. Compr. Cancer Netw. 17, 506–513 (2019).
NICE. Prostate cancer: diagnosis and management. NICE https://www.nice.org.uk/guidance/ng131 (2019).
Le Bihan, D. et al. Separation of diffusion and perfusion in intravoxel incoherent motion MR imaging. Radiology 168, 497–505 (1988).
Bowden, D. & Barrett, T. Angiogenesis imaging in Neoplasia. J. Clin. Imaging Sci. 1, 38 (2011).
PubMed PubMed Central Article Google Scholar
Kasivisvanathan, V. et al. MRI-targeted or standard biopsy for prostate-cancer diagnosis. N. Engl. J. Med. 378, 1767–1777 (2018).
PubMed PubMed Central Article Google Scholar
van der Leest, M. et al. Head-to-head comparison of transrectal ultrasound-guided prostate biopsy versus multiparametric prostate resonance imaging with subsequent magnetic resonance-guided biopsy in biopsy-naïve men with elevated prostate-specific antigen: a large prospective Mu. Eur. Urol. 75, 570–578 (2019).
Ahmed, H. U. et al. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet 389, 815–822 (2017).
Rouvière, O. et al. Use of prostate systematic and targeted biopsy on the basis of multiparametric MRI in biopsy-naive patients (MRI-FIRST): a prospective, multicentre, paired diagnostic study. Lancet Oncol. 20, 100–109 (2019).
Turkbey, B. et al. Prostate imaging reporting and data system version 2.1: 2019 update of prostate imaging reporting and data system version 2. Eur. Urol. 76, 340–351 (2019).
Venderink, W. et al. Multiparametric magnetic resonance imaging for the detection of clinically significant prostate cancer: what urologists need to know. Part 3: targeted biopsy. Eur. Urol. 77, 481–490 (2020).
Padhani, A. R. et al. PI-RADS steering committee: the PI-RADS multiparametric MRI and MRI-directed biopsy pathway. Radiology 292, 464–474 (2019).
Schoots, I. G. & Padhani, A. R. Risk-adapted biopsy decision based on prostate magnetic resonance imaging and prostate-specific antigen density for enhanced biopsy avoidance in first prostate cancer diagnostic evaluation. BJU Int. 127, 175–178 (2021).
Sathianathen, N. J. et al. Negative predictive value of multiparametric magnetic resonance imaging in the detection of clinically significant prostate cancer in the prostate imaging reporting and data system era: a systematic review and meta-analysis. Eur. Urol. 78, 402–414 (2020).
Park, K. J., Choi, S. H., Kim, M. H., Kim, J. K. & Jeong, I. G. Performance of prostate imaging reporting and data system version 2.1 for diagnosis of prostate cancer: a systematic review and meta-analysis. J. Magn. Reson. Imaging 54, 103–112 (2021).
Westphalen, A. C. et al. Variability of the positive predictive value of PI-RADS for prostate MRI across 26 centers: experience of the society of abdominal radiology prostate cancer disease-focused panel. Radiology 296, 76–84 (2020).
Radtke, J. P. et al. Multiparametric magnetic resonance imaging (MRI) and MRI–transrectal ultrasound fusion biopsy for index tumor detection: correlation with radical prostatectomy specimen. Eur. Urol. 70, 846–853 (2016).
Tan, N. et al. Characteristics of detected and missed prostate cancer foci on 3-T multiparametric MRI using an endorectal coil correlated with whole-mount thin-section histopathology. Am. J. Roentgenol. 205, W87–W92 (2015).
Langer, D. L. et al. Intermixed normal tissue within prostate cancer: effect on MR imaging measurements of apparent diffusion coefficient and T2-sparse versus dense cancers. Radiology 249, 900–908 (2008).
Serrao, E. M. et al. Investigating the ability of multiparametric MRI to exclude significant prostate cancer prior to transperineal biopsy. J. Can. Urol. Assoc. 9, E853–E858 (2015).
Salami, S. S. et al. Biologic significance of magnetic resonance imaging invisibility in localized prostate cancer. JCO Precis. Oncol. https://doi.org/10.1200/po.19.00054 (2019).
Article PubMed PubMed Central Google Scholar
Esses, S. J., Taneja, S. S. & Rosenkrantz, A. B. Imaging facilities’ adherence to PI-RADS v2 minimum technical standards for the performance of prostate MRI. Acad. Radiol. 25, 188–195 (2018).
Burn, P. R. et al. A multicentre assessment of prostate MRI quality and compliance with UK and international standards. Clin. Radiol. 74, 894.e19–894.e25 (2019).
Rouvière, O., Souchon, R. & Melodelima, C. Pitfalls in interpreting positive and negative predictive values: application to prostate multiparametric magnetic resonance imaging. Diagn. Interv. Imaging 99, 515–518 (2018).
Barentsz, J. O. et al. ESUR prostate MR guidelines 2012. Eur. Radiol. 22, 746–757 (2012).
PubMed PubMed Central Article Google Scholar
Weinreb, J. C. et al. PI-RADS prostate imaging — reporting and data system: 2015, version 2. Eur. Urol. 69, 16–40 (2016).
Sackett, J. et al. Quality of prostate MRI: is the PI-RADS standard sufficient? Acad. Radiol. 28, 199–207 (2021).
van der Leest, M., Israël, B., Engels, R. R. M. & Barentsz, J. O. Reply to Arnaldo Stanzione, Massimo Imbriaco, and Renato Cuocolo’s Letter to the Editor re: Marloes van der Leest, Bas Israël, Eric Bastiaan Cornel, et al. High diagnostic performance of short magnetic resonance imaging protocols for prostate cancer detection in biopsy-naïve men: the next step in magnetic resonance imaging accessibility. Eur. Urol. 2019;76:574-81. Are we meeting our standards? Stringent prostate imaging reporting and data system acquisition requirements might be limiting prostate accessibility. Eur. Urol. 77, e58–e59 (2020).
Stabile, A. et al. Factors influencing variability in the performance of multiparametric magnetic resonance imaging in detecting clinically significant prostate cancer: a systematic literature review. Eur. Urol. Oncol. 3, 145–167 (2020).
PubMed PubMed Central Article Google Scholar
Akin, O. et al. Interactive dedicated training curriculum improves accuracy in the interpretation of MR imaging of prostate cancer. Eur. Radiol. 20, 995–1002 (2010).
PubMed PubMed Central Article Google Scholar
Gaziev, G. et al. Defining the learning curve for multiparametric magnetic resonance imaging (MRI) of the prostate using MRI-transrectal ultrasonography (TRUS) fusion-guided transperineal prostate biopsies as a validation tool. BJU Int. 117, 80–86 (2016).
Stolk, T. T. et al. False positives in PIRADS (V2) 3, 4, and 5 lesions: relationship with reader experience and zonal location. Abdom. Radiol. 44, 1044–1051 (2019).
Hansen, N. L. et al. Comparison of initial and tertiary centre second opinion reads of multiparametric magnetic resonance imaging of the prostate prior to repeat biopsy. Eur. Radiol. 27, 2259–2266 (2017).
Wibmer, A. et al. Diagnosis of extracapsular extension of prostate cancer on prostate MRI: Impact of second-opinion readings by subspecialized genitourinary oncologic radiologists. Am. J. Roentgenol. 205, W73–W78 (2015).
Ecke, T. H. et al. Comparison of initial and second opinion reads of multiparametric magnetic resonance imaging of the prostate for transperineal template-guided biopsies with MRI-Ultrasound fusion. Urol. Oncol. Semin. Orig. Investig. 39, 781.e1–781.e7 (2021).
de Rooij, M. et al. ESUR/ESUI consensus statements on multi-parametric MRI for the detection of clinically significant prostate cancer: quality requirements for image acquisition, interpretation and radiologists’ training. Eur. Radiol. 30, 5404–5416 (2020).
PubMed PubMed Central Article Google Scholar
Barrett, T. et al. Certification in reporting multiparametric magnetic resonance imaging of the prostate: recommendations of a UK consensus meeting. BJU Int. 127, 304–306 (2021).
Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71, 209–249 (2021).
NHS. Cancer referral to treatment period start date. NHS https://www.datadictionary.nhs.uk/data_elements/cancer_referral_to_treatment_period_start_date.html (2022).
Redaniel, M. T., Martin, R. M., Gillatt, D., Wade, J. & Jeffreys, M. Time from diagnosis to surgery and prostate cancer survival: a retrospective cohort study. BMC Cancer 13, 559 (2013).
PubMed PubMed Central Article Google Scholar
Panebianco, V. et al. Clinical utility of multiparametric magnetic resonance imaging as the first-line tool for men with high clinical suspicion of prostate cancer. Eur. Urol. Oncol. 1, 208–214 (2018).
van der Leest, M. et al. High diagnostic performance of short magnetic resonance imaging protocols for prostate cancer detection in biopsy-naïve men: the next step in magnetic resonance imaging accessibility. Eur. Urol. 76, 574–581 (2019).
Kuhl, C. K. et al. Abbreviated biparametric prostate MR imaging in men with elevated prostate-specific antigen. Radiology 285, 493–505 (2017).
留言 (0)